Follow-Up After Curative Treatment for Stage I–III Breast Cancer
The 2026 ASCO guideline emphasizes risk-adapted survivorship care while reaffirming that routine imaging and laboratory testing to detect distant recurrence do not improve survival in asymptomatic patients.
1. History and Physical Examination
Clinical follow-up should be individualized according to recurrence risk, treatment received, patient preferences, and survivorship needs.
Recommended schedule:
- Years 1–3: Every 3–6 months
- Years 4–5: Every 6–12 months
- After 5 years: Annually
Each visit should include:
- Interval history
- Breast/chest wall examination
- Regional lymph node examination
- Evaluation for signs or symptoms of recurrence
- Assessment of treatment-related toxicities (lymphedema, neuropathy, menopausal symptoms, cardiotoxicity, bone health)
- Review of endocrine therapy adherence when applicable
- Counseling regarding healthy lifestyle, exercise, weight management, alcohol moderation, and smoking cessation
Virtual follow-up visits may be appropriate for selected patients.
2. Breast Imaging
After Breast-Conserving Surgery
- First mammogram 6–12 months after completion of radiation therapy (or approximately 1 year after the preoperative mammogram if radiation is omitted).
- Annual mammography thereafter.
After Unilateral Mastectomy
- Annual mammography of the contralateral breast.
After Bilateral Mastectomy
- Routine mammography is not recommended.
3. Breast MRI
Routine MRI surveillance is not recommended.
MRI should be reserved for patients who meet established high-risk screening criteria, including:
- BRCA1 or BRCA2 mutation
- TP53 or PALB2 mutation
- Lifetime breast cancer risk ≥20–25%
- Selected patients with very dense breasts and high genetic risk
4. Imaging for Distant Recurrence
Routine imaging is not recommended in asymptomatic patients.
Do not routinely obtain:
- CT scans
- PET/CT
- Bone scan
- Liver ultrasound
- Chest radiograph
- Brain MRI
These studies should only be performed when symptoms, physical examination, or laboratory findings suggest recurrence.
5. Laboratory Testing
Routine laboratory surveillance is not recommended.
Do not routinely obtain:
- Complete blood count (CBC)
- Comprehensive metabolic panel (CMP)
- Liver function tests
- Alkaline phosphatase
unless clinically indicated.
6. Tumor Markers
Routine measurement of serum tumor markers is not recommended.
Do not routinely obtain:
- CA 15-3
- CA 27.29
- CEA
in asymptomatic patients.
7. Circulating Tumor DNA (ctDNA)
Routine surveillance with circulating tumor DNA (ctDNA) is not recommended outside of clinical trials, as current evidence has not demonstrated an improvement in survival or quality of life when molecular recurrence is detected before clinical recurrence.
8. Survivorship Care
Survivorship visits should include:
- Management of endocrine therapy adherence
- Assessment of long-term toxicities
- Lymphedema screening
- Bone health assessment
- Cardiovascular risk reduction
- Exercise counseling
- Weight management
- Smoking cessation
- Alcohol moderation
- Psychosocial support
- Sexual health counseling
- Coordination with the primary care physician
Key Recommendations
- History and physical examination: Every 3–6 months for years 1–3, every 6–12 months for years 4–5, then annually.
- Annual mammography remains the only recommended routine surveillance imaging.
- Routine CT, PET/CT, bone scan, MRI, ultrasound, or chest X-ray are not recommended in asymptomatic patients.
- Routine CBC, chemistry panels, liver function tests, and tumor markers (CA 15-3, CA 27.29, CEA) are not recommended.
- Routine ctDNA surveillance is not recommended outside clinical trials.
- Follow-up should be individualized according to recurrence risk and survivorship needs, with increasing emphasis on healthy lifestyle interventions and management of treatment-related toxicities.
Reference:
Runowicz CD, et al. ASCO Guideline Update: Breast Cancer Follow-Up and Management After Primary Treatment. Journal of Clinical Oncology. 2026.
Rodrigo Arrangoiz MS, MD, FACS, FSSO 